Quintiles
| Public | |
| Traded as | NYSE: Q |
| Industry |
Contract Research Organization Pharmaceutical Service Consulting |
| Founded | 1982 |
| Headquarters | Durham, North Carolina, USA |
Key people |
Dennis Gillings, Founder Tom Pike CEO Kevin Gordon COO |
| Products | Support services for pharmaceutical, biotech and medical companies and individuals |
| Revenue |
 US$ Approximately $4.2 billion in Service Revenue (2014) |
Number of employees | ~ 35,000 (2015) |
| Website | http://www.quintiles.com/ |
Quintiles Transnational, INC (NYSE: Q), is a Fortune 500 company and the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 35,000 employees conducting business in approximately 100 countries.
Quintiles is the world’s largest contract research organization as ranked by reported service revenues, and is focused primarily on Phase II-IV clinical trials and associated laboratory and analytical services. Quintiles' Integrated Healthcare Services supports diverse functions, including contract pharmaceutical sales in many geographic markets, as well as a growing number of healthcare business services, such as outcome-based and payer/provider services.
History
In 1982, Gillings founded and incorporated Quintiles Transnational in North Carolina.[1]
Quintiles Transnational established Quintiles Pacific Inc. and Quintiles Ireland Ltd. in 1990, and in 1991 Quintiles GMBH was established in Germany and Quintiles Laboratories Ltd. was established in Atlanta, Georgia.
In September 1996, Quintiles purchased Innovex Ltd. of Britain for $747.5 million in stock and agreed to buy BRI International Inc.
Quintiles went public in 1997 and completed a successful secondary stock offering.
References
- ↑ Matthew Herper (November 22, 2010). "Money, Math and Medicine". Forbes Magazine. Retrieved July 21, 2011.